3195 completed. 3195 Phase 1, 876 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3195 | Completed 3195 |
| Phase 2 | 876 | Completed 876 |
Follow Nervous System Diseases: new trials by email Literature Review of Nervous System Diseases trials Research Report on Nervous System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) T25-Fast, Mycapssa, T25-Fed - Acromegaly | Phase 1 | Completed | Triastek (Shanghai) Limited | 18 | 2026-06-25 | 2026-09-16 |
| A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults ODT2 Test formulation, ODT Reference formulation - Migraine | Phase 1 | Completed | Pfizer | 36 | 2026-05-11 | 2026-09-04 |
| Acute Nicotine Gum and Tinnitus Loudness in Non-Smoking Adults Nicotine polacrilex gum 4 mg, Placebo gum - Tinnitus, Chronic Subjective Tinnitus | Phase 1 / Phase 2 | Completed | San Diego State University | 29 | 2026-03-25 | 2026-10-16 |
| Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity Modafinil, Oxiracetam, Pramiracetam - Healthy, Cognition | Phase 1 | Completed | Abdulraheem Mohamed Gouda | 70 | 2026-03-09 | 2026-10-01 |
| A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants GRT6019 - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Completed | Grünenthal GmbH | 24 | 2026-01-06 | 2026-08-12 |
| Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects YN001, Rosuvastatin calcium Tablets - Atherosclerotic Cardiovascular Diseases, Cerebrovascular Diseases | Phase 1 | Completed | Beijing Inno Medicine Co., Ltd. | 24 | 2025-12-08 | 2026-09-23 |
| A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants GRT6019 - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Completed | Grünenthal GmbH | 18 | 2025-11-21 | 2026-02-13 |
| Study of BB-025, Alone and After BB-031, in Healthy Volunteers BB-025, BB-031 - Pharmacodynamics, Pharmacokinetics | Phase 1 | Completed | Basking Biosciences, Inc. | 72 | 2025-11-05 | 2026-04-06 |
| Test-retest Study With [18F]FBB in Cardiac Amyloidosis Florbetaben F18 - Cardiac Amyloidosis | Phase 1 | Completed | Lantheus Germany GmbH | 15 | 2025-10-21 | 2026-10-23 |
| BHV-7000 Responsive Neurostimulation System (RNS) Study BHV-700 - Epilepsy, Seizures | Phase 1 | Completed | Yale University | 5 | 2025-10-07 | 2026-10-21 |
| A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants LTG-001 SDD, LTG-001 Formulation A Prototype 1, LTG-001 Formulation B Prototype 2 - Pain Management | Phase 1 | Completed | Latigo Biotherapeutics | 14 | 2025-10-06 | 2026-01-14 |
| Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine) A-DOPAMINE - Parkinson Disease | Phase 1 / Phase 2 | Completed | University Hospital, Lille | 1 | 2025-10-01 | 2026-05-22 |
| Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2) - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 8 | 2025-09-29 | 2026-04-03 |
| Intraoperative Midazolam on Delirium Outcome of Elderly Patients Midazolam, Saline - Delirium, Anxiety | Phase 1 | Completed | Chinese PLA General Hospital | 612 | 2025-09-01 | 2026-09-02 |
| CGM-Guided Acarbose for Painful Diabetic Neuropathy Acarbose 50 mg, Placebo - Diabetes, Diabetes Complications | Phase 1 | Completed | Shifa International Hospital | 170 | 2025-09-01 | 2026-03-03 |
| Clinical Trial of the Safety and Tolerability of the Drug MMH-450 in Healthy Volunteers MMH-450 - Sleep Disorders | Phase 1 | Completed | Materia Medica Holding | 18 | 2025-08-15 | 2026-08-04 |
| Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI CBD/CBD-A, Placebo - SCI - Spinal Cord Injury, Neuropathic Pain | Phase 1 / Phase 2 | Completed | University of Miami | 6 | 2025-06-16 | 2026-08-14 |
| A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects PRT-064040 nasal spray, Placebo - Migraine | Phase 1 | Completed | Sichuan Purity Pharmaceutical Technology Co., Ltd. | 80 | 2025-06-07 | 2025-12-04 |
| Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) Stiripentol capsule (Diacomit®), Stiripentol oral suspension (Diacomit®) - Dravet Syndrome, Epilepsy | Phase 1 | Completed | Biocodex | 24 | 2025-06-01 | 2025-09-16 |
| A Study of HBS-201 (Pitolisant Delayed-release) HBS-201 - Narcolepsy | Phase 1 | Completed | Harmony Biosciences Management, Inc. | 46 | 2025-05-21 | 2025-12-12 |
Showing 20 of 3195. Sign in to see all of them.
Alzheimer Disease (385) · Brain Neoplasms (316) · Parkinson Disease (278) · Glioblastoma (216) · Central Nervous System Neoplasms (189) · Astrocytoma (173) · Stroke (172) · Glioma (148) · Gliosarcoma (144) · Multiple Sclerosis (133) · Oligodendroglioma (123) · Epilepsy (112) · Migraine Disorders (77) · Amyotrophic Lateral Sclerosis (76) · Spinal Cord Injuries (75)
Central Nervous System Diseases (2086) · Brain Diseases (1853) · Neurodegenerative Diseases (904) · Pathological Conditions, Signs and Symptoms (812) · Mental Disorders (664) · Signs and Symptoms (577) · Neurologic Manifestations (565) · Neoplasms (536) · Neoplasms by Site (521) · Nervous System Neoplasms (485) · Neurocognitive Disorders (480) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (435) · Neoplasms by Histologic Type (433) · Neuromuscular Diseases (432)
Temozolomide (59) · Radiotherapy (46) · eslicarbazepine acetate (30) · opicapone (30) · Donepezil (28) · Sodium Chloride (26) · carbidopa, levodopa drug combination (26) · Irinotecan (23) · Carboplatin (20) · Everolimus (20) · Filgrastim (20) · Saline Solution (20) · Bevacizumab (19) · Lidocaine (17) · Sirolimus (17)
National Cancer Institute (NCI) (86) · Bial - Portela C S.A. (75) · GlaxoSmithKline (63) · National Institute of Neurological Disorders and Stroke (NINDS) (48) · Merck Sharp & Dohme LLC (43) · Pfizer (41) · Biogen (39) · Duke University (31) · Wyeth is now a wholly owned subsidiary of Pfizer (31) · Eli Lilly and Company (30) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (26) · AstraZeneca (25) · Mayo Clinic (25) · Johns Hopkins University (22) · National Institute of Allergy and Infectious Diseases (NIAID) (20)
United States (1924) · United Kingdom (188) · Canada (154) · Australia (121) · Germany (116) · France (113) · China (97) · Netherlands (86) · South Korea (72) · Spain (68) · Japan (63) · Belgium (62) · Sweden (54) · Italy (52) · Switzerland (38)
Danna Jennings, MD (9) · Henry S. Friedman, MD (9)
PMID 31072380, PMID 31420846, PMID 40680102, PMID 24524452, PMID 30741694, PMID 36602886, PMID 37171121, PMID 37996817, PMID 38588457, PMID 10816186, PMID 11927799, PMID 12119802, PMID 15117425, PMID 15738343, PMID 16030064, PMID 16614412, PMID 16896165, PMID 17351147, PMID 17562928, PMID 18323467, PMID 18342407, PMID 18713956, PMID 18787087, PMID 20734360, PMID 20876843, PMID 22163120, PMID 22338078, PMID 23377664, PMID 23545055, PMID 23860343, PMID 25789616, PMID 26823478, PMID 26925577, PMID 27243238, PMID 27423899, PMID 27955995, PMID 28403842, PMID 29063518, PMID 29063814, PMID 29671202, PMID 29688815, PMID 29749279, PMID 29862060, PMID 30124008, PMID 30134967, PMID 30355322, PMID 30361858, PMID 31005596, PMID 31048098, PMID 31127735
2014 (21), 2015 (21), 2017 (17), 2018 (16), 2016 (15), 2019 (13), UM1CA097452 (11), U01CA081457 (10), U01CA062475 (7), U01CA097452 (7), P30CA033572 (6), 2009 (5), 2023 (5), U01CA137443 (5), U10CA025224 (5)